ATE459364T1 - Verbesserte bakteriolyse-kombinationstherapie für die behandlung von tumoren - Google Patents

Verbesserte bakteriolyse-kombinationstherapie für die behandlung von tumoren

Info

Publication number: ATE459364T1
Authority: AT; Austria
Prior art keywords: tumors; microtubule; spores; agents; found
Prior art date: 2003-10-22

Application number

AT04809987T

Other languages

English (en)

Inventor

Long Dang

Chetan Bettegowda

Kenneth Kinzler

Bert Vogelstein

Original Assignee

Univ Johns Hopkins

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-22

Filing date

2004-10-21

Publication date

2010-03-15

2004-10-21 Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins

2010-03-15 Application granted granted Critical

2010-03-15 Publication of ATE459364T1 publication Critical patent/ATE459364T1/de

Links

206010028980 Neoplasm Diseases 0.000 title abstract 8
238000002648 combination therapy Methods 0.000 title 1
102000029749 Microtubule Human genes 0.000 abstract 5
108091022875 Microtubule Proteins 0.000 abstract 5
210000004688 microtubule Anatomy 0.000 abstract 5
239000003795 chemical substances by application Substances 0.000 abstract 4
241000894006 Bacteria Species 0.000 abstract 1
206010021143 Hypoxia Diseases 0.000 abstract 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
229940123237 Taxane Drugs 0.000 abstract 1
238000013459 approach Methods 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
230000017531 blood circulation Effects 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
230000006378 damage Effects 0.000 abstract 1
229960003668 docetaxel Drugs 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000002008 hemorrhagic effect Effects 0.000 abstract 1
230000001146 hypoxic effect Effects 0.000 abstract 1
238000010253 intravenous injection Methods 0.000 abstract 1
231100000782 microtubule inhibitor Toxicity 0.000 abstract 1
230000017074 necrotic cell death Effects 0.000 abstract 1
210000005170 neoplastic cell Anatomy 0.000 abstract 1
239000003381 stabilizer Substances 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1
DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 1
230000001988 toxicity Effects 0.000 abstract 1
231100000419 toxicity Toxicity 0.000 abstract 1
241001148471 unidentified anaerobic bacterium Species 0.000 abstract 1
230000002792 vascular Effects 0.000 abstract 1
GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 abstract 1
229960002066 vinorelbine Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/842—Clostridium

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Mycology (AREA)
Zoology (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT04809987T 2003-10-22 2004-10-21 Verbesserte bakteriolyse-kombinationstherapie für die behandlung von tumoren ATE459364T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US51292303P	2003-10-22	2003-10-22
PCT/US2004/034625 WO2005039492A2 (en)	2003-10-22	2004-10-21	Improved combination bacteriolytic therapy for the treatment of tumors

Publications (1)

Publication Number	Publication Date
ATE459364T1 true ATE459364T1 (de)	2010-03-15

Family

ID=34520062

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04809987T ATE459364T1 (de)	2003-10-22	2004-10-21	Verbesserte bakteriolyse-kombinationstherapie für die behandlung von tumoren

Country Status (5)

Country	Link
US (3)	US8007782B2 (de)
EP (1)	EP1675465B1 (de)
AT (1)	ATE459364T1 (de)
DE (1)	DE602004025834D1 (de)
WO (1)	WO2005039492A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102009017908A1 (de) *	2009-04-17	2010-10-21	Kist-Europe Forschungsgesellschaft Mbh	Vektor für den Transport von mikrobiologischen Organismen zu Krankheitsherden
HRP20200793T1 (hr)	2011-05-09	2020-10-16	Mayo Foundation For Medical Education And Research	Liječenje raka
CA2917407C (en)	2012-10-01	2023-03-14	Mayo Foundation For Medical Education And Research	Complexes containing albumin-containing nanoparticles and antibodies to treat cancer
TWI664976B (zh)	2013-01-02	2019-07-11	美商迪科生物系統公司	使用細菌治療癌症之組成物和方法
US9522876B2 (en)	2013-03-15	2016-12-20	Zymeworks Inc.	Cytotoxic and anti-mitotic compounds, and methods of using the same
RU2718670C2 (ru)	2013-03-29	2020-04-13	Байомед Вэлли Дискавериз, Инк.	C. novyi для лечения солидных опухолей человека
WO2014160967A2 (en) *	2013-03-29	2014-10-02	Biomed Valley Discoveries, Inc.	C. novyi for the treatment of solid tumors in non-human animals
ES2916722T3 (es)	2013-12-27	2022-07-05	Zymeworks Inc	Sistemas de enlace que contienen sulfonamida para conjugados de fármacos
SG11201605260VA (en)	2013-12-27	2016-07-28	Zymeworks Inc	Var2csa-drug conjugates
WO2015183978A1 (en)	2014-05-28	2015-12-03	Agensys, Inc.	Derivatives of dolaproine-dolaisoleuine peptides
CA2950926A1 (en)	2014-06-13	2015-12-17	Mayo Foundation For Medical Education And Research	Albumin-bound paclitaxel nanoparticle/rituximab complexes for treatment of cd20-expressing lymphomas
JP6600651B2 (ja)	2014-06-16	2019-10-30	マヨファウンデーションフォーメディカルエデュケーションアンドリサーチ	骨髄腫の治療
EP2998000A1 (de) *	2014-09-16	2016-03-23	University College Cork-National University of Ireland, Cork	Kombinationstherpie bei krebs
EP3194421B1 (de)	2014-09-17	2021-11-03	Zymeworks Inc.	Cytotoxische und antimitotische verbindungen und verfahren zur verwendung davon
US9446148B2 (en)	2014-10-06	2016-09-20	Mayo Foundation For Medical Education And Research	Carrier-antibody compositions and methods of making and using the same
WO2016123313A1 (en)	2015-01-29	2016-08-04	Oxyrase, Inc.	Methods for inhibiting tumor growth
TW201707725A (zh)	2015-08-18	2017-03-01	美國馬友醫藥教育研究基金會	載體－抗體組合物及其製造及使用方法
TW201713360A (en)	2015-10-06	2017-04-16	Mayo Foundation	Methods of treating cancer using compositions of antibodies and carrier proteins
EP3399861A4 (de)	2016-01-07	2019-08-07	Mayo Foundation for Medical Education and Research	Verfahren zur behandlung von krebs mit interferon
US11351254B2 (en)	2016-02-12	2022-06-07	Mayo Foundation For Medical Education And Research	Hematologic cancer treatments
EP3432926A4 (de)	2016-03-21	2019-11-20	Mayo Foundation for Medical Education and Research	Verfahren zur verminderung der toxizität eines chemotherapeutikums
CA3018340A1 (en)	2016-03-21	2017-09-28	Mayo Foundation For Medical Education And Research	Methods for improving the therapeutic index for a chemotherapeutic drug
US10618969B2 (en)	2016-04-06	2020-04-14	Mayo Foundation For Medical Education And Research	Carrier-binding agent compositions and methods of making and using the same
EP3506950A1 (de)	2016-09-01	2019-07-10	Mayo Foundation for Medical Education and Research	Gegen t-zell-karzinome gerichtete verfahren und zusammensetzungen
JP7525999B2 (ja)	2016-09-01	2024-07-31	マヨファウンデーションフォーメディカルエデュケーションアンドリサーチ	キャリアー－ｐｄ－ｌ１結合剤組成物及び癌を処置する為にそれを使用する方法
RU2756892C2 (ru) *	2016-09-06	2021-10-06	Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч	Композиции с паклитакселом, альбумином и связывающим средством и способы их применения и получения
CN109843924A (zh)	2016-09-06	2019-06-04	梅约医学教育与研究基金会	治疗表达pd-l1的癌症的方法
EP3509635A1 (de)	2016-09-06	2019-07-17	Vavotar Life Sciences LLC	Verfahren zur behandlung von dreifach negativem brustkrebs unter verwendung von zusammensetzungen aus antikörpern und trägerproteinen
GB201801977D0 (en) *	2018-02-07	2018-03-28	Knauf Insulation Doo Skofja Loka	Recycling
CN111001014B (zh) *	2019-12-12	2022-04-22	四川大学华西医院	一种基于固定细菌做载体的抗肿瘤药物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5688517A (en) *	1993-01-29	1997-11-18	Napro Biotherapeutics, Inc.	Method for assessing sensitivity of tumor cells to cephalomannine and 10-deacetyltaxol
US5554638A (en) *	1993-05-24	1996-09-10	Duke University	Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders
ES2227667T3 (es) *	1996-02-02	2005-04-01	Zentaris Gmbh	Metodo para la inactivacion de proteinas de la subfamilia ras y agentes para ello.
EP1446012B1 (de) *	2001-11-21	2013-07-17	The Johns Hopkins University	Bakteriolytische kombinationstherapie für die behandlung von tumoren
ITMI20012497A1 (it)	2001-11-28	2003-05-28	Agriplast S N C	Perfezionamento nei tubi per l'irrigazione a goccia
WO2005039491A2 (en) *	2003-10-22	2005-05-06	The John Hopkins University	Certain improved combination bacteriolytic therapy for the treatment of tumors

2004
- 2004-10-21 AT AT04809987T patent/ATE459364T1/de not_active IP Right Cessation
- 2004-10-21 EP EP04809987A patent/EP1675465B1/de not_active Expired - Lifetime
- 2004-10-21 WO PCT/US2004/034625 patent/WO2005039492A2/en not_active Ceased
- 2004-10-21 DE DE602004025834T patent/DE602004025834D1/de not_active Expired - Lifetime
- 2004-10-21 US US10/568,765 patent/US8007782B2/en active Active
2011
- 2011-08-05 US US13/198,850 patent/US8613917B2/en not_active Expired - Fee Related
2013
- 2013-12-16 US US14/106,987 patent/US9572843B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US20140328813A1 (en)	2014-11-06
US20110311500A1 (en)	2011-12-22
US8613917B2 (en)	2013-12-24
EP1675465B1 (de)	2010-03-03
EP1675465A4 (de)	2008-07-30
EP1675465A2 (de)	2006-07-05
WO2005039492A3 (en)	2005-06-30
DE602004025834D1 (de)	2010-04-15
US20070148135A1 (en)	2007-06-28
WO2005039492A9 (en)	2005-06-02
US9572843B2 (en)	2017-02-21
US8007782B2 (en)	2011-08-30
WO2005039492A2 (en)	2005-05-06

Legal Events

Date	Code	Title	Description
2010-09-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE602004025834D1 (de)	2010-04-15	Die behandlung von tumoren
Renschler	2004	The emerging role of reactive oxygen species in cancer therapy
Wilde et al.	2018	Autophagy in cancer: a complex relationship
Liu et al.	2015	Protecting the normal in order to better kill the cancer
López-Lázaro	2007	Dual role of hydrogen peroxide in cancer: possible relevance to cancer chemoprevention and therapy
De Ridder et al.	2008	Hypoxic tumor cell radiosensitization through nitric oxide
Dick et al.	2010	Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy
Dorie et al.	1997	Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine
Kapper et al.	2024	Targeting ferroptosis in ovarian cancer: novel strategies to overcome chemotherapy resistance
Qu et al.	2010	Bexarotene: a promising anticancer agent
Luo et al.	2012	Electron transfer-based combination therapy of cisplatin with tetramethyl-p-phenylenediamine for ovarian, cervical, and lung cancers
Roomi et al.	2006	Inhibition of pulmonary metastasis of melanoma B16FO cells in C57BL/6 mice by a nutrient mixture consisting of ascorbic acid, lysine, proline, arginine, and green tea extract
Vazana-Barad et al.	2013	Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma
Tannock et al.	2023	Cell proliferation, drug distribution and therapeutic effects in relation to the vascular system of solid tumours
Douple	1985	The use of platinum chemotherapy to potentiate radiotherapy
NO20050793L (no)	2005-04-18	Anvendelse av urease for inhibering av kreftcellevekst
WO2005039491A3 (en)	2005-06-23	Certain improved combination bacteriolytic therapy for the treatment of tumors
Masunaga	1999	Modification of tirapazamine-induced cytotoxicity in combination with mild hyperthermia and/or nicotinamide: reference to effect on quiescent tumour cells
Friedmann et al.	2006	Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer
Engblom et al.	1999	Carboplatin–paclitaxel‐and carboplatin–docetaxel‐induced cytotoxic effect in epithelial ovarian carcinoma in vitro
Watanabe et al.	2007	Comparison of the antivascular and cytotoxic activities of TZT-1027 (Soblidotin) with those of other anticancer agents
McCarty et al.	2007	A two-phase strategy for treatment of oxidant-dependent cancers
Chen et al.	2004	Radiation therapy concurrent with weekly paclitaxel for locoregionally advanced nasopharyngeal carcinoma: outcomes of a phase I trial
Khan et al.	2024	Cuproptosis: A Copper-Triggered Unique Cell Death Targeting Cancer.
Watanabe et al.	2006	Antivascular effects of TZT‐1027 (Soblidotin) on murine Colon26 adenocarcinoma